Andrew H Wei
Overview
Explore the profile of Andrew H Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
10980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
12.
Wei A, Loo S, Daver N, Daver N
Blood
. 2024 Sep;
PMID: 39316723
Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating agents or low-dose cytarabine. This ended a semi-centennial...
13.
Loo S, Potter N, Ivey A, ONions J, Moon R, Jovanovic J, et al.
Blood
. 2024 Sep;
144(24):2554-2557.
PMID: 39316646
Pretransplant detection of KMT2Ar measurable residual disease ≥0.001% by quantitative polymerase chain reaction was associated with significantly inferior posttransplant survival (2-year relapse-free survival 17% vs 59%; P = .001) and...
14.
Dohner H, DiNardo C, Appelbaum F, Craddock C, Dombret H, Ebert B, et al.
Blood
. 2024 Aug;
144(21):2169-2173.
PMID: 39133932
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an...
15.
Dohner H, Pratz K, DiNardo C, Wei A, Jonas B, Pullarkat V, et al.
Blood
. 2024 Aug;
144(21):2211-2222.
PMID: 39133921
The European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems are based on response to intensive chemotherapy; their ability to discriminate outcomes in older patients treated with venetoclax-azacitidine...
16.
Diepstraten S, Yuan Y, La Marca J, Young S, Chang C, Whelan L, et al.
Cancer Cell
. 2024 Apr;
42(5):850-868.e9.
PMID: 38670091
TP53-mutant blood cancers remain a clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins, inducing cancer cell apoptosis. Despite acting downstream of p53, functional p53 is required for maximal cancer cell...
17.
Cortes J, Jonas B, Schiller G, Mims A, Roboz G, Wei A, et al.
Leuk Lymphoma
. 2024 Mar;
65(8):1145-1152.
PMID: 38538632
Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML). Here we report efficacy and safety of olutasidenib in 18...
18.
Tiong I, Wall M, Bajel A, Kalro A, Fleming S, Roberts A, et al.
Blood Cancer J
. 2024 Mar;
14(1):54.
PMID: 38531863
Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental...
19.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
J Clin Oncol
. 2024 Mar;
42(15):1766-1775.
PMID: 38471061
Purpose: Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of () AML. These patients are routinely treated with a FLT3 inhibitor...
20.
Tiong I, Hiwase D, Abro E, Bajel A, Palfreyman E, Beligaswatte A, et al.
J Clin Oncol
. 2024 Mar;
42(18):2161-2173.
PMID: 38427924
Purpose: A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. Methods:...